Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the perugia multidisciplinary team for thoracic tumors

Vienna Ludovini, Lorenza Pistola, Vanesa Gregorc, Irene Floriani, Eliana Rulli, Luciana Di Carlo, Antonia Semeraro, Giuliano Daddi, Samir Darwish, Lucia Stocchi, Francesca Romana Tofanetti, Guido Bellezza, Angelo Sidoni, Rita Tognellini, Lucio Crinò, Maurizio Tonato

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aims and background. The aim of this study was to evaluate the relationship between a panel of biological markers (p53, Bcl-2, HER-2, Ki67, DNA ploidy and S-phase fraction) and clinical-pathological parameters and its impact on outcome in non-small cell lung cancer (NSCLC). Methods and study design. Tumor tissue specimens obtained after surgical resection were collected from consecutive patients with NSCLC. We used an immunocyto-chemical technique for p53, Bcl-2, HER-2 and Ki67 analysis in fine-needle aspirates obtained from surgical samples that were also evaluated by flow cytometric DNA analysis using a FACScan flow cytometer. Results. From April 2000 to December 2005, 136 patients with radically resected NSCLC were recruited. Median age was 66 years (range, 31-84 years), male/female ratio 117/19, ECOG performance status 0/1 127/4, stage I/II/III 76/25/35, squamous/adenocarcinoma/large-cell/mixed histology 62/49/17/8, smokers yes/no 121/11. Positivity of p53, Bcl-2, HER-2 and Ki67 was detected in 51.4%, 27.9%, 25.0% and 55.8% of the samples, respectively; 82.9% of the cases revealed aneuploid DNA histograms and 56.7% presented an S-phase fraction of more than 12%. Statistically significant associations between high Ki67 and poorly differentiated tumors (P = 0.016) and a smoking history (P = 0.053); p53 positivity and high Ki67 (P = 0.002); HER-2 positivity and adenocarcinoma subtype (P = 0.015) and presence of lymph node involvement (P = 0.006); and Bcl-2 positivity and squamous cell carcinoma subtype (P= 0.058) were observed. At univariate analysis, high Ki67 proved to be the only marker associated with disease-free survival (P = 0.047). After adjusting for stage, none of the examined immunocytochemical markers emerged as an independent factor for disease-free and overall survival; only pathological stage was identified as an independent prognostic factor for disease-free survival (P = 0.0001) and overall survival (P = 0.0001). In the group of 76 patients classified as TNM stage I, high Ki67 was the only marker associated with recurrence of disease (P= 0.05). Conclusions. Our data do not support a relevant prognostic role of immunocyto-chemical markers in NSCLC, even if the Ki67 index might have particular relevance to identify patients with more aggressive tumors who are at high risk for disease relapse.

Original languageEnglish
Pages (from-to)398-405
Number of pages8
JournalTumori
Volume94
Issue number3
Publication statusPublished - May 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Thorax
Biomarkers
Disease-Free Survival
DNA
S Phase
Neoplasms
Adenocarcinoma
Recurrence
Ploidies
Aneuploidy
Needles
Squamous Cell Carcinoma
Histology
Lymph Nodes
Smoking
History
Survival

Keywords

  • Bd-2
  • DNA ploidy
  • HER-2
  • Ki67
  • Non-small cell lung cancer
  • p53
  • Prognosis
  • S-phase fraction

ASJC Scopus subject areas

  • Cancer Research

Cite this

Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the perugia multidisciplinary team for thoracic tumors. / Ludovini, Vienna; Pistola, Lorenza; Gregorc, Vanesa; Floriani, Irene; Rulli, Eliana; Di Carlo, Luciana; Semeraro, Antonia; Daddi, Giuliano; Darwish, Samir; Stocchi, Lucia; Tofanetti, Francesca Romana; Bellezza, Guido; Sidoni, Angelo; Tognellini, Rita; Crinò, Lucio; Tonato, Maurizio.

In: Tumori, Vol. 94, No. 3, 05.2008, p. 398-405.

Research output: Contribution to journalArticle

Ludovini, V, Pistola, L, Gregorc, V, Floriani, I, Rulli, E, Di Carlo, L, Semeraro, A, Daddi, G, Darwish, S, Stocchi, L, Tofanetti, FR, Bellezza, G, Sidoni, A, Tognellini, R, Crinò, L & Tonato, M 2008, 'Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the perugia multidisciplinary team for thoracic tumors', Tumori, vol. 94, no. 3, pp. 398-405.
Ludovini, Vienna ; Pistola, Lorenza ; Gregorc, Vanesa ; Floriani, Irene ; Rulli, Eliana ; Di Carlo, Luciana ; Semeraro, Antonia ; Daddi, Giuliano ; Darwish, Samir ; Stocchi, Lucia ; Tofanetti, Francesca Romana ; Bellezza, Guido ; Sidoni, Angelo ; Tognellini, Rita ; Crinò, Lucio ; Tonato, Maurizio. / Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the perugia multidisciplinary team for thoracic tumors. In: Tumori. 2008 ; Vol. 94, No. 3. pp. 398-405.
@article{5dc16859562345fda5ff585bdc111839,
title = "Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the perugia multidisciplinary team for thoracic tumors",
abstract = "Aims and background. The aim of this study was to evaluate the relationship between a panel of biological markers (p53, Bcl-2, HER-2, Ki67, DNA ploidy and S-phase fraction) and clinical-pathological parameters and its impact on outcome in non-small cell lung cancer (NSCLC). Methods and study design. Tumor tissue specimens obtained after surgical resection were collected from consecutive patients with NSCLC. We used an immunocyto-chemical technique for p53, Bcl-2, HER-2 and Ki67 analysis in fine-needle aspirates obtained from surgical samples that were also evaluated by flow cytometric DNA analysis using a FACScan flow cytometer. Results. From April 2000 to December 2005, 136 patients with radically resected NSCLC were recruited. Median age was 66 years (range, 31-84 years), male/female ratio 117/19, ECOG performance status 0/1 127/4, stage I/II/III 76/25/35, squamous/adenocarcinoma/large-cell/mixed histology 62/49/17/8, smokers yes/no 121/11. Positivity of p53, Bcl-2, HER-2 and Ki67 was detected in 51.4{\%}, 27.9{\%}, 25.0{\%} and 55.8{\%} of the samples, respectively; 82.9{\%} of the cases revealed aneuploid DNA histograms and 56.7{\%} presented an S-phase fraction of more than 12{\%}. Statistically significant associations between high Ki67 and poorly differentiated tumors (P = 0.016) and a smoking history (P = 0.053); p53 positivity and high Ki67 (P = 0.002); HER-2 positivity and adenocarcinoma subtype (P = 0.015) and presence of lymph node involvement (P = 0.006); and Bcl-2 positivity and squamous cell carcinoma subtype (P= 0.058) were observed. At univariate analysis, high Ki67 proved to be the only marker associated with disease-free survival (P = 0.047). After adjusting for stage, none of the examined immunocytochemical markers emerged as an independent factor for disease-free and overall survival; only pathological stage was identified as an independent prognostic factor for disease-free survival (P = 0.0001) and overall survival (P = 0.0001). In the group of 76 patients classified as TNM stage I, high Ki67 was the only marker associated with recurrence of disease (P= 0.05). Conclusions. Our data do not support a relevant prognostic role of immunocyto-chemical markers in NSCLC, even if the Ki67 index might have particular relevance to identify patients with more aggressive tumors who are at high risk for disease relapse.",
keywords = "Bd-2, DNA ploidy, HER-2, Ki67, Non-small cell lung cancer, p53, Prognosis, S-phase fraction",
author = "Vienna Ludovini and Lorenza Pistola and Vanesa Gregorc and Irene Floriani and Eliana Rulli and {Di Carlo}, Luciana and Antonia Semeraro and Giuliano Daddi and Samir Darwish and Lucia Stocchi and Tofanetti, {Francesca Romana} and Guido Bellezza and Angelo Sidoni and Rita Tognellini and Lucio Crin{\`o} and Maurizio Tonato",
year = "2008",
month = "5",
language = "English",
volume = "94",
pages = "398--405",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the perugia multidisciplinary team for thoracic tumors

AU - Ludovini, Vienna

AU - Pistola, Lorenza

AU - Gregorc, Vanesa

AU - Floriani, Irene

AU - Rulli, Eliana

AU - Di Carlo, Luciana

AU - Semeraro, Antonia

AU - Daddi, Giuliano

AU - Darwish, Samir

AU - Stocchi, Lucia

AU - Tofanetti, Francesca Romana

AU - Bellezza, Guido

AU - Sidoni, Angelo

AU - Tognellini, Rita

AU - Crinò, Lucio

AU - Tonato, Maurizio

PY - 2008/5

Y1 - 2008/5

N2 - Aims and background. The aim of this study was to evaluate the relationship between a panel of biological markers (p53, Bcl-2, HER-2, Ki67, DNA ploidy and S-phase fraction) and clinical-pathological parameters and its impact on outcome in non-small cell lung cancer (NSCLC). Methods and study design. Tumor tissue specimens obtained after surgical resection were collected from consecutive patients with NSCLC. We used an immunocyto-chemical technique for p53, Bcl-2, HER-2 and Ki67 analysis in fine-needle aspirates obtained from surgical samples that were also evaluated by flow cytometric DNA analysis using a FACScan flow cytometer. Results. From April 2000 to December 2005, 136 patients with radically resected NSCLC were recruited. Median age was 66 years (range, 31-84 years), male/female ratio 117/19, ECOG performance status 0/1 127/4, stage I/II/III 76/25/35, squamous/adenocarcinoma/large-cell/mixed histology 62/49/17/8, smokers yes/no 121/11. Positivity of p53, Bcl-2, HER-2 and Ki67 was detected in 51.4%, 27.9%, 25.0% and 55.8% of the samples, respectively; 82.9% of the cases revealed aneuploid DNA histograms and 56.7% presented an S-phase fraction of more than 12%. Statistically significant associations between high Ki67 and poorly differentiated tumors (P = 0.016) and a smoking history (P = 0.053); p53 positivity and high Ki67 (P = 0.002); HER-2 positivity and adenocarcinoma subtype (P = 0.015) and presence of lymph node involvement (P = 0.006); and Bcl-2 positivity and squamous cell carcinoma subtype (P= 0.058) were observed. At univariate analysis, high Ki67 proved to be the only marker associated with disease-free survival (P = 0.047). After adjusting for stage, none of the examined immunocytochemical markers emerged as an independent factor for disease-free and overall survival; only pathological stage was identified as an independent prognostic factor for disease-free survival (P = 0.0001) and overall survival (P = 0.0001). In the group of 76 patients classified as TNM stage I, high Ki67 was the only marker associated with recurrence of disease (P= 0.05). Conclusions. Our data do not support a relevant prognostic role of immunocyto-chemical markers in NSCLC, even if the Ki67 index might have particular relevance to identify patients with more aggressive tumors who are at high risk for disease relapse.

AB - Aims and background. The aim of this study was to evaluate the relationship between a panel of biological markers (p53, Bcl-2, HER-2, Ki67, DNA ploidy and S-phase fraction) and clinical-pathological parameters and its impact on outcome in non-small cell lung cancer (NSCLC). Methods and study design. Tumor tissue specimens obtained after surgical resection were collected from consecutive patients with NSCLC. We used an immunocyto-chemical technique for p53, Bcl-2, HER-2 and Ki67 analysis in fine-needle aspirates obtained from surgical samples that were also evaluated by flow cytometric DNA analysis using a FACScan flow cytometer. Results. From April 2000 to December 2005, 136 patients with radically resected NSCLC were recruited. Median age was 66 years (range, 31-84 years), male/female ratio 117/19, ECOG performance status 0/1 127/4, stage I/II/III 76/25/35, squamous/adenocarcinoma/large-cell/mixed histology 62/49/17/8, smokers yes/no 121/11. Positivity of p53, Bcl-2, HER-2 and Ki67 was detected in 51.4%, 27.9%, 25.0% and 55.8% of the samples, respectively; 82.9% of the cases revealed aneuploid DNA histograms and 56.7% presented an S-phase fraction of more than 12%. Statistically significant associations between high Ki67 and poorly differentiated tumors (P = 0.016) and a smoking history (P = 0.053); p53 positivity and high Ki67 (P = 0.002); HER-2 positivity and adenocarcinoma subtype (P = 0.015) and presence of lymph node involvement (P = 0.006); and Bcl-2 positivity and squamous cell carcinoma subtype (P= 0.058) were observed. At univariate analysis, high Ki67 proved to be the only marker associated with disease-free survival (P = 0.047). After adjusting for stage, none of the examined immunocytochemical markers emerged as an independent factor for disease-free and overall survival; only pathological stage was identified as an independent prognostic factor for disease-free survival (P = 0.0001) and overall survival (P = 0.0001). In the group of 76 patients classified as TNM stage I, high Ki67 was the only marker associated with recurrence of disease (P= 0.05). Conclusions. Our data do not support a relevant prognostic role of immunocyto-chemical markers in NSCLC, even if the Ki67 index might have particular relevance to identify patients with more aggressive tumors who are at high risk for disease relapse.

KW - Bd-2

KW - DNA ploidy

KW - HER-2

KW - Ki67

KW - Non-small cell lung cancer

KW - p53

KW - Prognosis

KW - S-phase fraction

UR - http://www.scopus.com/inward/record.url?scp=48249087719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249087719&partnerID=8YFLogxK

M3 - Article

C2 - 18705409

AN - SCOPUS:48249087719

VL - 94

SP - 398

EP - 405

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 3

ER -